Evidence map›Paper›PMID 41484630›Full record

ArticleJournal of translational medicine2026

Hypoxia-induced PRMT6 expression promotes temozolomide chemoresistance in glioblastoma via G3BP1.

Shuyang Chen, Peng Yu, Yongqing Sun, Yuting Yan, Boxiang Zhang, Guangyu Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuyang Chen *Department of Neurosurgery, The First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, Liaoning, 110001, China.
Peng Yu *Department of Neurosurgery, The First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, Liaoning, 110001, China.
Yongqing Sun *Department of Neurosurgery, The First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, Liaoning, 110001, China.
Yuting YanDepartment of Neurosurgery, The First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, Liaoning, 110001, China.
Boxiang ZhangDepartment of Neurosurgery, The First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, Liaoning, 110001, China.
Guangyu LiDepartment of Neurosurgery, The First Affiliated Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, Liaoning, 110001, China. gyli@cmu.edu.cn.

Funding

the Science and Technology foundation of Liaoning, China 2023JH2/101300045the Science and Technology foundation of Shenyang, China 223213307
6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM), the most aggressive primary brain tumor, is associated with extremely poor patient prognosis. Temozolomide (TMZ) resistance remains a major cause of treatment failure. Protein arginine methyltransferase 6 (PRMT6) plays critical roles in tumorigenesis, but its function and regulatory mechanisms in GBM TMZ resistance have not been elucidated. While the hypoxic microenvironment is a hallmark feature of GBM, its epigenetic regulatory mechanisms in drug resistance remain unclear.

methodsWe analyzed PRMT6 expression and prognostic value in GBM using public databases (TCGA, CGGA). TMZ resistance was assessed through in vitro assays (CCK-8, flow cytometry, colony formation) and in vivo xenograft models. Molecular mechanisms of the HIF-1α/PRMT6/G3BP1 axis were investigated via RNA sequencing, ChIP-qPCR, dual-luciferase reporter assays, and co-immunoprecipitation.

resultsPRMT6 was highly expressed in GBM and correlated with poor prognosis. Hypoxia transcriptionally activated PRMT6 through HIF-1α. Elevated PRMT6 expression promoted TMZ resistance, while its knockdown enhanced drug sensitivity. Mechanistically, PRMT6 interacted with transcription factor GABPA to upregulate stress granule core protein G3BP1, subsequently suppressing pro-apoptotic BCL2L13 and conferring chemoresistance. In vivo studies confirmed that both PRMT6 and G3BP1 significantly influenced TMZ resistance.

conclusionThis study provides evidence that hypoxia mediates TMZ resistance in GBM through the HIF-1α/PRMT6/G3BP1 axis, identifying PRMT6 and G3BP1 as promising therapeutic targets to overcome chemoresistance.

Indexed as

Brain NeoplasmsDNA HelicasesDrug Resistance, NeoplasmGlioblastomaNuclear ProteinsProtein-Arginine N-MethyltransferasesRNA Recognition Motif ProteinsTemozolomideAnimalsApoptosisCell HypoxiaCell Line, TumorGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitMiceDNA HelicasesG3BP1 protein, humanHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitNuclear ProteinsPoly-ADP-Ribose Binding ProteinsPRMT6 protein, humanProtein-Arginine N-MethyltransferasesRNA HelicasesRNA Recognition Motif ProteinsTemozolomideG3BP1GlioblastomaHIF-1αHypoxic microenvironmentPRMT6Temozolomide resistance

Identifiers

PMID41484630
PMCPMC12903591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.